GlassScriptPhysician profile
Harshad Ratilal Mehta
NPI 1942281217
$1,919.50
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,481 · 2020: $413 · 2024: $26.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $26.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $26.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $351.82 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $291.21 | 2019-2020 | |
| Biotronik INC. | $271.63 | 2019-2020 | |
| Pfizer INC. | $254.96 | 2019-2020 | |
| Amgen INC. | $146.85 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $122.63 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $110.94 | 2019-2020 | |
| Boston Scientific Corporation | $71.10 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.29 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $42.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $37.04 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $33.77 | 2019 | |
| Amarin Pharma, INC. | $30.21 | 2019 | |
| Edwards Lifesciences Corporation | $26.12 | 2024 | |
| Novo Nordisk INC | $20.68 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $18.66 | 2019 | |
| Abbott Laboratories | $16.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harshad Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.